TrialInvestigational new drugs2013

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Tanguy Seiwert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.